Geode Capital Management
DTIL icon

Geode Capital Management’s Precision BioSciences DTIL Stock Holding History

Geode Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Buy
287,090
+61,433
+27% +$283K ﹤0.01% 3213
2025
Q4 		$939K Buy
225,657
+116,136
+106% +$659K ﹤0.01% 3401
2025
Q3 		$605K Buy
109,521
+31,809
+41% +$152K ﹤0.01% 3545
2025
Q2 		$326K Buy
77,712
+4,025
+5% +$19.9K ﹤0.01% 3701
2025
Q1 		$352K Buy
73,687
+9,146
+14% +$46.6K ﹤0.01% 3666
2024
Q4 		$246K Sell
64,541
-1,433
-2% -$10.5K ﹤0.01% 3836
2024
Q3 		$591K Buy
65,974
+19,088
+41% +$184K ﹤0.01% 3538
2024
Q2 		$456K Buy
46,886
+17,043
+57% +$201K ﹤0.01% 3592
2024
Q1 		$405K Sell
29,843
-4
-0% -$49 ﹤0.01% 3688
2023
Q4 		$327K Buy
29,847
+2,752
+10% +$29.7K ﹤0.01% 3768
2023
Q3 		$277K Buy
27,095
+1,368
+5% +$21K ﹤0.01% 3847
2023
Q2 		$406K Sell
25,727
-1,644
-6% -$37.6K ﹤0.01% 3730
2023
Q1 		$619K Buy
27,371
+39
+0.1% +$1.28K ﹤0.01% 3568
2022
Q4 		$975K Buy
27,332
+1,292
+5% +$51.1K ﹤0.01% 3350
2022
Q3 		$1.01M Buy
26,040
+8,775
+51% +$417K ﹤0.01% 3376
2022
Q2 		$828K Sell
17,265
-13,229
-43% -$777K ﹤0.01% 3510
2022
Q1 		$2.82M Sell
30,494
-126
-0.4% -$17.1K ﹤0.01% 3077
2021
Q4 		$6.8M Buy
30,620
+1,040
+4% +$290K ﹤0.01% 2710
2021
Q3 		$10.2M Buy
29,580
+3,540
+14% +$1.2M ﹤0.01% 2440
2021
Q2 		$9.78M Buy
26,040
+2,007
+8% +$603K ﹤0.01% 2472
2021
Q1 		$7.46M Buy
24,033
+2,482
+12% +$869K ﹤0.01% 2560
2020
Q4 		$5.39M Buy
21,551
+1,577
+8% +$387K ﹤0.01% 2564
2020
Q3 		$3.69M Buy
19,974
+6,945
+53% +$1.38M ﹤0.01% 2566
2020
Q2 		$3.25M Buy
13,029
+2,469
+23% +$541K ﹤0.01% 2561
2020
Q1 		$1.91M Buy
10,560
+1,118
+12% +$293K ﹤0.01% 2693
2019
Q4 		$3.93M Buy
9,442
+4,741
+101% +$1.49M ﹤0.01% 2599
2019
Q3 		$1.18M Buy
4,701
+122
+3% +$39.7K ﹤0.01% 3170
2019
Q2 		$1.82M Buy
+4,579
New +$1.84M ﹤0.01% 3012

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management's DTIL Position: Q1 2026 in Review

Geode Capital Management increased its Precision BioSciences (DTIL) stake by 27% in Q1 2026, buying an estimated $283K and bringing the position to 287,090 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3213.

Geode Capital Management first reported a position in DTIL in Q2 2019 and has held it in 28 quarters since. The position peaked at $10.2M in Q3 2021. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Geode Capital Management held 287,090 shares of Precision BioSciences worth $1.58M as of Q1 2026.
  • Geode Capital Management bought 61,433 Precision BioSciences shares in Q1 2026, an estimated $283K.
  • Precision BioSciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3213 holding.
  • Geode Capital Management first reported a position in Precision BioSciences in Q2 2019 and has held it in 28 quarters since.
  • Geode Capital Management's Precision BioSciences position peaked at $10.2M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.